Who Wins When 35 Blockbuster Drugs Lose Patents in 2011 and 2012?
OTCJournal Newsletter
February 7, 2011 Volume XII, Issue 12 Home Page : www.otcjournal.com Email Questions or Comments To: editor@otcjournal.com To OTC Journal Members: Who Wins When 35 Blockbuster Drugs Lose Patents in 2011 and 2012 On Saturday I urged you to check your inbox after the market closed today for a new trading idea. As promised, here it is…. I think you`ll see why I was so empathic about you being ready. And, I`m equally confident you`ll agree this stock is something worth owning beginning tomorrow, and at least through the better part of 2011.
The underlying attraction to this small cap is real simple – the revenue lightswitch is being flipped on this very quarter. Ergo, a stock that has largely been on the shelf for quite some time is now being dusted off and put into action by the investor community.
Veteran traders will immediately recognize the kind of upside potential this story has. In the same sense that the market loves turnaround stories and drives a stock`s price higher once the corner has been turned, when the `pre` is dropped from a pre-revenue company, investors often go hog-wild. You know how this is likely to go though – every day you wait to step in puts you further down on the list of any rally`s biggest beneficiaries.
The company is Genmed Holding Corp. (GENM), and if you haven`t heard of it yet, just wait – fireworks are about go off, and you`ll want to be around for them.
Overview Genmed is, or soon will be, a generic drug distributor. This company has been outwardly on hold for the last couple years while waiting for approval from the European medical community. Though the only thing they initially requested distribution approval for was paracetamol – or acetaminophen – it`s still an amazingly long process. More important, that license was awarded in December.
Inwardly though, Genmed has spent the last couple of years preparing to hit the ground running when this day finally came.
Just to drive home the `ready to roll` point that current shareholders are going to enjoy, Genmed has already inked a five year distribution deal with one of the largest pharmaceutical distribution networks in the UK. The pain-killer and fever reducer will be pushed out to the distributor`s network of more than 1200 pharmacies and 150 hospitals sometime in Q3 of this year. The follow-up deal with the same distributor led to the funding of an advertising budget that will put Genmed`s products in the distributor`s marketing materials.
Just to put the pace of the company`s efforts into perspective, all this happened within just a month of paracetamol being approved in most of Western Europe.
Other distribution channels are currently being negotiated, but given how fast the first one materialized, others can`t be too far down the road.
And here`s the thing to chew on that the rest of the market isn`t yet…. the seven European countries where paracetamol is currently approved aren`t the only potential market for Genmed`s drugs, nor is paracetamol the only drug Genmed is seeking approval for. There are actually seven generic drugs the company is currently interested in, and technically speaking, the only geographical boundaries Genmed has to contend with are approvals to market these drugs on those countries. The company has already said Spain is the next target market though, with other markets in its sights.
In other words, the potential growth and profit trail that GENM investors could follow here has no immediate end in sight.
But wait – it gets even better.
Scope of the Opportunity I don`t know how closely you`ve been following this slow (but accelerating) expiration of patents for some major drugs over the last few years, but 2011 and 2012 may be the watershed year that makes the generic drug industry the norm, and the branded-drug industry the minority. Well, Genmed is poised perfectly for that brewing storm.
The turning of the tide over the next couple of years will be driven by 35 major drugs losing their patented status, including Viagra, Zyprexa, Singulair, and Lexapro just to name a few. Any and all of those 35 names could be a generic drug opportunity for Genmed.
There`s one data nugget, however, that really drives home just how big the paradigm shift could be for generic drug makers and distributors like Genmed. What`s that Goldman Sachs thinks the `innovator` drug market could lose as much as 49% of tits business to the generic drug market by 2015.
All told, by 2014, the global generic drug market could be worth $130 billion (yes, with a `b`). By 2015, some experts think it could be worth as much as $150 billion.
Wow.
Now compare that to Genmed`s mere $70 million market cap. How little of that total $130 billion market will the company need to capture to become a smashing success A mere 1.0% of that total translates into $1.3 billion. Let`s be even more conservative than that though. Let`s just say Genmed only captures 0.25% of that total generic market early on. That`s about $325 million per year versus that $70 million market cap.
See where this is going Teva is currently priced at 3 times annual sales. Mylan is priced at 1.3 times its annual revenue. Dr. Reddy`s currently trades at 3.8 times its annual top line figure. Assuming a P/S ratio of 3.0 is the `right` number, and conservatively assuming that Genmed can capture just 0.25% of the globe`s total generic market, you could make the case the GENM should almost be a billion dollar company ($325 million x 3.0).
Will it get there tomorrow No, but that`s why I said you`ll want to start owning tomorrow but simultaneously be willing to hold it at least through the end of the year. See, as investors start to crunch these same numbers, I think it will start to accelerate toward that level of valuation, doling out the biggest rewards to the stock`s earliest investors. The longer you own it, the more time Genmed has to capture market share by adding more generic drugs to its stable, and tapping more markets.
Make no mistake though – the genesis of these potential gains is now, and based on the volume swell over the last few weeks, the market`s starting to nibble. If you want a shot at making the most money with this idea from here, you`ll want to be in a position before the numbers behind this story spread any further.
——————————————————————– Refer A Friend If you find the OTC Journal informative and profitable, please forward our newsletter alert service to like-minded friends and associates who share similar market interests.
——————————————————————– Ensure Newsletter Delivery To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don`t miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.
Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.
——————————————————————– Disclaimer The OTC Journal Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as described below, this publication accepts compensation from certain of the companies which it features. Likewise, this newsletter, which is owned by MarketByte, LLC also accepts compensation in connection with the dissemination of informationregarding the companies featured. This newsletter should not, therefore, be regarded as an independent publication.
Go Here to view our compensation on every company we have ever covered, or visit the following web address:
http://www.otcjournal.com/disclosure/compensation/section/profile/
for our full profiles and http://www.otcjournal.com/disclosure/compensation/section/alert/
for Trading Alerts. MarketByte LLC has been paid a fee of $12,000 by BlueWave Advisors for publishing content on the Company.
All statements and opinions expressed herein are those of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation of an offer to buy or sell any securities mentioned. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.
From time to time MarketByte, LLC sells shares in the open market it receives as compensation for coverage of client companies.
Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
The editor, members of the editor`s family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are discouraged by company policy from owning, buying, selling or otherwise trading stock for their own benefit in the companies who appear in the publication unless such activities are specifically disclosed in the newsletter or on the OTC Journal web site. Full disclosure of position changes is updated on the web site weekly.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED IN THIS PUBLICATION.
INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at http://www.finra.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC`s EDGAR page. The NASD has published information on how to invest carefully at its web site. MarketByte LLC`s mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.
The information found in this newsletter is protected by the copyright laws of the united states and may not be copied, or reproduced in any way without the expressed, written consent of the editors of otcjournal.com.
——————————————————————- You can
Related posts:
- Pharma Trading Alert- Genmed Holding Corporation (OTC- GENM)
- OTCStockExchange GENM News Alert
- GENM +38%, IPRC +37%! DIAAF Should Now Be On Everyones Watch Lists!!
- Watch List for Friday 1-21-2011
- Who Wins When 35 Blockbuster Drugs Lose Patents in 2011 and 2012?